Cargando…

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i

The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Mapelli, Massimo, Mantegazza, Valentina, Ferrari, Cristina, Cimino, Roberto, Maragna, Riccardo, Pontone, Gianluca, Pepi, Mauro, Agostoni, Piergiuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192298/
https://www.ncbi.nlm.nih.gov/pubmed/36907832
http://dx.doi.org/10.1002/ehf2.14344
_version_ 1785043599195373568
author Mapelli, Massimo
Mantegazza, Valentina
Ferrari, Cristina
Cimino, Roberto
Maragna, Riccardo
Pontone, Gianluca
Pepi, Mauro
Agostoni, Piergiuseppe
author_facet Mapelli, Massimo
Mantegazza, Valentina
Ferrari, Cristina
Cimino, Roberto
Maragna, Riccardo
Pontone, Gianluca
Pepi, Mauro
Agostoni, Piergiuseppe
author_sort Mapelli, Massimo
collection PubMed
description The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on haemodialysis treated with sacubitril/valsartan and SGLT2i. At 10‐month follow‐up, the patient normalized left ventricle and atrial volumes and improved ejection fraction to the normal range, assessed both by echocardiography and cardiac magnetic resonance. Cardiac biomarkers and exercise performance improved consensually. The haemodialysis protocol and the loop diuretic dose were unchanged within the whole period.
format Online
Article
Text
id pubmed-10192298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101922982023-05-19 Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i Mapelli, Massimo Mantegazza, Valentina Ferrari, Cristina Cimino, Roberto Maragna, Riccardo Pontone, Gianluca Pepi, Mauro Agostoni, Piergiuseppe ESC Heart Fail Case Report The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on haemodialysis treated with sacubitril/valsartan and SGLT2i. At 10‐month follow‐up, the patient normalized left ventricle and atrial volumes and improved ejection fraction to the normal range, assessed both by echocardiography and cardiac magnetic resonance. Cardiac biomarkers and exercise performance improved consensually. The haemodialysis protocol and the loop diuretic dose were unchanged within the whole period. John Wiley and Sons Inc. 2023-03-12 /pmc/articles/PMC10192298/ /pubmed/36907832 http://dx.doi.org/10.1002/ehf2.14344 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Mapelli, Massimo
Mantegazza, Valentina
Ferrari, Cristina
Cimino, Roberto
Maragna, Riccardo
Pontone, Gianluca
Pepi, Mauro
Agostoni, Piergiuseppe
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title_full Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title_fullStr Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title_full_unstemmed Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title_short Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
title_sort dramatic disease regression in a case of hfref with end‐stage renal failure treated with sacubitril/valsartan and sglt2i
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192298/
https://www.ncbi.nlm.nih.gov/pubmed/36907832
http://dx.doi.org/10.1002/ehf2.14344
work_keys_str_mv AT mapellimassimo dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT mantegazzavalentina dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT ferraricristina dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT ciminoroberto dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT maragnariccardo dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT pontonegianluca dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT pepimauro dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i
AT agostonipiergiuseppe dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i